Pediatrix (MD) Q2 EPS Jumps 56%

Pediatrix Medical Group (NYSE:MD), a leader in neonatal and maternal-fetal healthcare services, reported its second-quarter 2025 earnings on August 5, 2025. The company delivered a standout quarter, with non-GAAP earnings per share (EPS) of $0.53, beating analyst expectations of $0.42 by 25.9% (non-GAAP). While revenue (GAAP) edged above forecasts at $468.8 million, Pediatrix’s net revenue declined 7.4% compared to the first quarter of 2024, mostly due to business divestitures. Overall, Pediatrix turned in a profitable period, signaled confidence for the year ahead, and showed core strength in its hospital-based practice areas. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Pediatrix specializes in comprehensive neonatal and maternal-fetal medical services. It operates more than 350 Neonatal Intensive Care Units (NICUs) in 30 states and employs over 1,300 neonatal physicians. The company partners with almost 400 hospitals and reported that approximately 67% of its net revenue was generated in its five largest states during 2024, with Texas contributing about one-third.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool